1. Introduction {#sec1-diagnostics-10-00446}
===============

Cystic fibrosis (CF) is a life-limiting autosomal recessive disorder that affects about 1 in 2500--4000 babies in the Caucasian population \[[@B1-diagnostics-10-00446]\]. The classical CF phenotype is characterized by lung disease (bronchiectasis with persistent airway-based infection and inflammation) and exocrine pancreatic insufficiency associated with nutrient malabsorption, contributing to impaired growth and undernutrition \[[@B2-diagnostics-10-00446]\]. CF is due to mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator *(CFTR*) anion channel \[[@B3-diagnostics-10-00446]\]. The most common *CFTR* mutation associated with cystic fibrosis is Phe508del (c.1521_1523delCTT, DF508) \[[@B4-diagnostics-10-00446]\]. Although the pancreatic status is closely related to the *CFTR* genotype \[[@B5-diagnostics-10-00446]\], there is a wide clinical heterogeneity in CF patients, even between those carrying the same *CFTR* genotype or between siblings with CF \[[@B6-diagnostics-10-00446]\].

The survival of individuals with CF has increased over the last 30 years, with a current predicted median age of survival of 43 years \[[@B7-diagnostics-10-00446]\]. This is due to many factors, including earlier diagnosis through cystic fibrosis newborn screening (CF NBS) \[[@B8-diagnostics-10-00446]\]. NBS strategies have been implemented since the early 1970s, and CF NBS is currently a widely accepted public health strategy in economically developed countries. All CF NBS strategies that are currently performed in NBS programs start with immunoreactive trypsinogen (IRT) on blood spots, usually in combination with a second IRT test (IRT2), pancreatitis-associated protein (PAP) on blood, or *CFTR* mutation analysis (DNA) \[[@B8-diagnostics-10-00446]\]. A pancreatic meconium lactase assay (LACT) is an additional strategy in CF NBS programs that is used in some regions after the first immunoreactive trypsinogen (IRT1) dosage \[[@B9-diagnostics-10-00446]\]. The European Cystic Fibrosis Society established that NBS programs should aim for a minimum sensitivity of 95% \[[@B10-diagnostics-10-00446]\]. Individuals identified by NBS can be diagnosed with CF by a sweat chloride value ≥60 mmol/L and/or by the identification of two CF-causing mutations in trans \[[@B11-diagnostics-10-00446]\]. Because CF NBS is widespread, most CF diagnoses presently occur in asymptomatic or minimally symptomatic babies following a positive NBS result \[[@B12-diagnostics-10-00446],[@B13-diagnostics-10-00446],[@B14-diagnostics-10-00446]\], and this unequivocally benefits short- and long-term outcomes \[[@B15-diagnostics-10-00446]\]. The presence of NBS may lead to an erroneous reassurance that all CF cases are identified at birth \[[@B16-diagnostics-10-00446]\]. Maclean et al. showed that access to CF NBS seems not to result in a delay in diagnosis or poorer outcomes in those children for whom CF was not detected by CF NBS \[[@B17-diagnostics-10-00446]\], but the question is debated \[[@B18-diagnostics-10-00446],[@B19-diagnostics-10-00446]\]. Estimating the annual number of false negatives (FNs) in the CF NBS program is a complex challenge that depends on the sensitivity of the NBS method. It is essential for NBS laboratories and CF referral centers to have feedback on new CF cases not diagnosed by screening that allows the quality of the NBS program to be evaluated. Fritz et al. estimated that there were 70 FNs in 4,038,560 screened newborns per year in the USA using either the IRT/DNA or IRT/IRT strategy \[[@B19-diagnostics-10-00446]\]. Rock et al. described the many possible causes of FN results that can occur after newborn screening for CF \[[@B20-diagnostics-10-00446]\]. Farrel et al. declared that every physician's first duty is to diagnose CF accurately and promptly because the "diagnosis is the first step of treatment" \[[@B21-diagnostics-10-00446]\]. To limit irreversible organ pathology, a timely diagnosis of CF for a precocious institution of CF therapies can greatly benefit these FN patients. Several case reports of delayed diagnosis after a false-negative CF NBS have been described in the current literature \[[@B20-diagnostics-10-00446],[@B22-diagnostics-10-00446],[@B23-diagnostics-10-00446],[@B24-diagnostics-10-00446]\]. The study of Padoan et al. analyzed 15 FN patients of the same CF center in Lombardy, a region in the northwest of Italy \[[@B25-diagnostics-10-00446]\]. Calvin et al. reviewed 30 years of CF NBS in East Anglia, England, and evaluated 29 FN patients, including 10 FN patients with meconium ileus \[[@B26-diagnostics-10-00446]\].

In Tuscany, a region in central Italy consisting of 3.7 million inhabitants, CF NBS has been carried out from 1984 in the CF Center of Florence \[[@B27-diagnostics-10-00446],[@B28-diagnostics-10-00446]\]. In our center, all patients, who were residents of Tuscany, were also referred for the sweat test if they had symptoms suggestive of CF. We retrospectively evaluated CF patients who were born in Tuscany in the 1992--2018 period and who had negative results in CF NBS but who were later diagnosed because they had symptoms suggestive of CF. The aim of the study was to investigate FNs through the following characteristics: the symptoms and signs suggesting CF, the age of diagnosis, the current pancreatic status, the genotypical features, and the results of sweat tests.

2. Materials and Methods {#sec2-diagnostics-10-00446}
========================

From 1992 to 2018, we retrospectively reviewed all the results from the CF NBS database of the Regional Referral CF Center in Florence. The previous data were not analyzed in this study because the CF NBS protocol before 1992 was performed using a test with low sensitivity (\<85%). Since 1992, the NBS has been performed by an immunoreactive trypsin (IRT) assay on dried blood spots, which is followed, if positive, by IRT retesting (IRT2) and meconium lactase dosage (protocol IRT1/IRT2 + LACT).

The cutoff of IRT1 was set at the 99th percentile, changing every 4--6 months according to NBS results and on the basis of seasons, as described in literature \[[@B29-diagnostics-10-00446],[@B30-diagnostics-10-00446]\]. In 1992--1993, we used a colorimetric method for dried blood spot analysis of IRT1 (Medical System, IRT1 99th: 55 ng/mL). Successively, fluorimetric methods were used for IRT1 analysis (Delfia in 1994--2005, IRT1 99th percentile range: 54--62 ng/mL; Auto-Delfia in 2006--2013, IRT1 99th percentile range: 57--63 ng/mL). Since 2014, the IRT1 analysis has been performed by using the GSP instrument (Perkin Elmer), with an IRT1 99th percentile range of 49--50 ng/mL. Meconium lactase was detected by glucose production after incubation of meconium with lactose (cutoff 0.5 U/g), as described from Pederzini et al. \[[@B9-diagnostics-10-00446]\]. The IRT2, taken at 3 or 4 weeks of age, followed the same procedure as the initial IRT1 assay (1992--2013 cutoff 29 ng/mL; 2014--2018 cutoff 23 ng/mL).

Since 2011, the NBS algorithm has been integrated with DNA analysis (protocol IRT1/IRT2 + LACT + IRT1/DNA); the overall Tuscany CF NBS strategy is illustrated in [Figure 1](#diagnostics-10-00446-f001){ref-type="fig"} \[[@B31-diagnostics-10-00446]\]. The detection rate of *CFTR* panel mutations through NBS was 80% until 2015 (38 CF-causing mutations were screened), 88% from 2016 to May 2018 (66 CF-causing mutations were screened), and 90% from May to December 2018 (272 CF-causing mutations were screened). In the database, we evaluated the total number of newborns screened, the true positives, the false positives, the true negatives, and the CF newborns with meconium ileus. In true-positive cases, all the patients with cystic fibrosis screening positive inconclusive diagnoses (CFSPIDs) who had developed CF during the follow-up (until 31 December 2019) were included \[[@B31-diagnostics-10-00446],[@B32-diagnostics-10-00446]\].

Subsequently, with an extensive review of our clinical chart, we isolated the CF patients born in Tuscany over these 26 years but with negative screening (FNs) and a CF diagnosis preceding 31 December 2019. CF was first clinically suspected, following which a sweat test was performed according to the consensus statement \[[@B11-diagnostics-10-00446]\]. The sweat chloride levels were tested according to the guidelines provided by the classic Gibson and Cook method \[[@B27-diagnostics-10-00446]\] in the single laboratory of the Florence CF Center. The signs and symptoms of FN patients that prompted the physician or pediatrician (in primary care or in hospital care) to suspect CF were extensively examined from clinical charts. We also retrospectively assessed the age at diagnosis (in years) of the FN patients and the values of sweat chloride. The clinical symptoms revealed in our databases have been divided into these 10 categories:Respiratory (bronchopulmonary infections, chronic cough, expectoration)Gastroenteric (irregular defecation, frequent episodes of diarrhea)Failure to thrive (not meeting standards of growth)Salt-loss syndrome (dehydration with metabolic hypochloremic alkalosis)Nasal polyposisPancreatitisLiver diseaseDiabetesDistal bowel obstruction syndrome (DIOS)Azoospermia

Pancreatic sufficiency (PS) was defined based on at least two values of fecal pancreatic elastase being higher than 200 μg/g, measured independently of acute gastrointestinal diseases \[[@B33-diagnostics-10-00446]\].

A genotype assessment was performed in all CF patients. We carried out gene sequencing (98% detection rate) in all CF patients, where one mutation was found after a first-level analysis of NBS. In all cases, an informed consent form was signed.

We analyzed the *CFTR* mutation alleles of FN patients and compared these with the *CFTR* alleles of true-positive patients. We compared the results with statistical analysis (chi-squared analysis with Yates correction) of the prevalence of the same mutations, which were more frequent in Tuscany for the true-positive cases than the FN cases. A *p*-value of less than 0.05 was considered statistically significant.

3. Results {#sec3-diagnostics-10-00446}
==========

In Tuscany, 746,686 newborns were screened in the 1992--2018 period. Throughout the 26-year period, both NBS protocols and diagnostic devices changed over time. In 2011, the IRT1/IRT2 + LACT algorithm was integrated with the analysis of mutations of the *CFTR* gene (IRT1/DNA), as reported in [Figure 1](#diagnostics-10-00446-f001){ref-type="fig"}. The sensitivity changed from 87.50% (1992--2010) to 96.15% (2011--2018). The CF incidence in the region over these 26 years was 1:3696 (1:3600 in the 1992--2010 period and 1:3939 in the 2011--2018 period). This showed that 202 patients had CF, of whom 162 (80.2%) were true-positive cases, 18 (8.9%) were FN cases, and 22 (10.9%) had meconium ileus. The CF newborns with meconium ileus had positive CF NBS results in 16/22 cases and FN results in 6/22. Patients with meconium ileus were excluded from the FN group and considered separately. The complete results of CF NBS are reported in [Table 1](#diagnostics-10-00446-t001){ref-type="table"}. The average age at diagnosis of 18 FN patients was 6.6 years (range: 4 months to 22 years; median: 0.9 years). The symptoms at diagnosis were respiratory infections (8/18, 44.4%), salt-loss syndrome (7/18, 38.8%), failure to thrive (6/18, 33.3%), diarrhea (4/18, 22.2%), and nasal polyposis (3/18, 16.6%). Data on the symptoms leading to CF diagnosis, IRT values, pancreatic status, sweat chloride values, and genotypes are reported in [Table 2](#diagnostics-10-00446-t002){ref-type="table"}. All FN patients had an IRT1 below the 99th percentile cutoff. Of the true-positive cases, 73.4% (119/160) had pancreatic deficiency. The frequencies of *CFTR* mutations detected in Tuscany are reported in [Table 3](#diagnostics-10-00446-t003){ref-type="table"}. The five most frequent *CFTR* mutations in Tuscany (DF508, G542X, L1065P, N1303K, and E585X) were significantly less common in FN cases (41.7% of alleles) than in true-positive cases (60.4% of alleles; *p* = 0.029). In the group of FN patients, there was also a significantly greater prevalence of alleles with unknown mutations (8.3% vs. 1.1%, *p* = 0.001).

4. Discussion {#sec4-diagnostics-10-00446}
=============

CF NBS offers the opportunity for early medical and nutritional intervention, leading to improved outcomes \[[@B8-diagnostics-10-00446]\]. In Tuscany, two NBS strategies were employed during the 26 years of this study. In the period during which DNA analysis was employed in the NBS algorithm (2011--2018), fewer FNs occurred, and the sensitivity improved from 87.50% to 96.15%. Overall, the screening program has proved effective in detecting 90.0% of CF cases at birth. The occurrence of FN results in CF newborns with meconium ileus (6/22 in our results) is reported in the literature \[[@B34-diagnostics-10-00446]\]. However, it is not a concern, as these patients must always undergo a sweat test \[[@B10-diagnostics-10-00446]\]. The situation of FN patients without meconium ileus who manifest CF symptoms at an older age is completely different, as a delay in diagnosis can compromise the nutritional status and lung function in such cases \[[@B35-diagnostics-10-00446],[@B36-diagnostics-10-00446]\].

A disadvantage of CF NBS, particularly in regions with high allelic *CFTR* heterogeneity, is the detection of false-positive cases and/or carriers of a single CF-causing mutation \[[@B8-diagnostics-10-00446]\]. Moreover, with the introduction of DNA analysis to the NBS algorithm, the number of CFSPID cases has increased \[[@B37-diagnostics-10-00446]\]. These aspects of NBS may cause diagnostic dilemmas and, consequently, unnecessary anxiety for the family \[[@B38-diagnostics-10-00446]\]. The problems associated with identifying CFSPID and/or mild cases of CF on NBS are well discussed by Munck et al. \[[@B32-diagnostics-10-00446]\].

Our results, similar to those of Calvin et al. \[[@B26-diagnostics-10-00446]\], have shown that the cutoff of IRT1 is the main determinant of sensitivity.

Our study focused on the symptoms suggestive of CF in 18 patients born in Tuscany with FN results in CF NBS. The symptoms suggestive of a CF diagnosis that prompt physicians to prescribe a sweat test are various in the literature; malnutrition and/or respiratory symptoms were the most common at the time of diagnosis \[[@B20-diagnostics-10-00446],[@B25-diagnostics-10-00446],[@B26-diagnostics-10-00446]\]. In case reports, the clinical symptoms of malnutrition and/or respiratory symptoms were also most common at the time of diagnosis \[[@B23-diagnostics-10-00446],[@B24-diagnostics-10-00446]\]. In Tuscany, respiratory symptoms (cough and respiratory infections), often in association with other clinical features (e.g., gastroenteric symptoms, failure to thrive, salt-loss syndrome), were the most common (44.2%). Metabolic alkalosis was noted in the prescreening literature as a prominent symptom before CF testing was available \[[@B39-diagnostics-10-00446],[@B40-diagnostics-10-00446]\]. Our results illustrate that, in our region, metabolic alkalosis was a frequent clinical event that led to CF diagnosis (38.8%) in FN cases. There could be an association between alkalosis and rare *CFTR* mutations such as S737F, which has already been shown to be associated with salt-loss syndrome at diagnosis \[[@B41-diagnostics-10-00446]\]. These data are different from those in the study of Padoan et al., where only 3 out of 15 FN patients (20.0%) in Lombardy had metabolic alkalosis at diagnosis \[[@B25-diagnostics-10-00446]\]. In the research of Calvin et al., carried out in a region of England, no cases with false-negative results had salt-loss syndrome at diagnosis \[[@B26-diagnostics-10-00446]\]. Another explanation of the higher frequency of salt-loss syndrome in Tuscany could be that this region has a hotter climate in comparison to the regions of Northern Italy and England. In our study, during the period in which DNA analysis was included in the protocol, all FN patients had salt-loss syndrome at diagnosis. The age at diagnosis for FN patients ranged from 4 months to 22 years, and CF was always diagnosed within the first year of life in the case of salt-loss syndrome.

We can speculate that if these FN patients had been somehow diagnosed by NBS, thanks to early saline supplementation, they probably would not have had salt-loss syndrome, a life-threatening event for an infant with CF. After the first year of life, respiratory symptoms, nasal polyposis, and the failure to thrive, associated with gastroenterological symptoms such as diarrhea, should lead the pediatrician to suspect CF. Only three FN patients presented with classical CF disease at diagnosis: respiratory and gastroenteric symptoms associated with failure to thrive (I, Q, R patients in [Table 2](#diagnostics-10-00446-t002){ref-type="table"}). Pancreatitis, liver disease, diabetes, and DIOS were not found to be onset CF symptoms for FN patients. Conversely, of the 15 FN cases in Lombardy \[[@B24-diagnostics-10-00446]\], 2 had recurrent abdominal pain and acute pancreatitis-like symptoms at diagnosis. In the literature, only one FN case was described with liver disease (cholestasis) at diagnosis \[[@B22-diagnostics-10-00446]\]. The presence of mild CF in FN patients must be reported, such as case A, in which the patient had no symptoms (the older brother with mild CF was born in the prescreening era), and case E, in which the patient was diagnosed at age 15 for mild respiratory symptoms. Usually, FNs have pancreatic sufficiency (13/18, 72.2%), which could reflect the less severe clinical features in these subjects compared to CF true-positive cases (pancreas sufficiency in 41/160, 26.6%).

When CF is suspected, the gold standard of diagnostic tests still remains the sweat test, which was frequently already abnormal upon the first determination in our series. Indeed, only three patients (C, O, P patients in [Table 2](#diagnostics-10-00446-t002){ref-type="table"}) had a borderline sweat test upon first determination and were CF-positive (chloride ≥60 mEq) upon subsequent determinations. These data confirm the need to repeat sweat chloride testing over time, especially for patients carrying *CFTR* mutations with varying clinical consequences \[[@B42-diagnostics-10-00446]\]. The presence of FNs, despite the presence of well-organized CF NBS, must recommend that one always keep a vigilant eye on the possibility that a patient may have CF.

The *CFTR* molecular analysis of true-positive cases and FNs revealed a high heterogeneity of *CFTR* allele mutations in Tuscany. DF508 accounted for only 45.6% of the CF cases, according to the data on the prevalence of about 50% of the alleles in the Italian population \[[@B43-diagnostics-10-00446]\]. In the FN cases, the most common mutations in Tuscany (DF508, G542X, L1065P, N1303K, and E585X), were found more rarely. This is the reason it is essential, in regions such as Tuscany with a high *CFTR* allelic heterogeneity, to always adopt NBS that analyzes a large panel of mutations to keep the sensitivity at high levels. The difficulty in planning the NBS strategy lies in balancing greater sensitivity with specificity and positive predictive value, thus avoiding the detection of CF carriers and inconclusive diagnoses. A key aspect in regions such as Tuscany with high *CFTR* allelic variability is that all mutations detected by screening must be CF-causing mutations. Another consideration based on these data is that when the suspicion of CF is strong, it is always necessary to perform a sweat test first. It is not prudent to trust the genetic test exclusively, given the high number of rare mutations, mutations with variable clinical consequences, and unknown mutations.

5. Conclusions {#sec5-diagnostics-10-00446}
==============

This study confirms the evidence that CF NBS is a valid public health strategy to detect the majority of CF cases at birth (90% in 26 years). While the sensitivity of CF NBS has been improved over the years, especially with the introduction of DNA analysis to the NBS algorithm, CF was not detected by screening in some babies because it was under the IRT1 cutoff. These patients (in total, 18 cases), born in Tuscany from 1992 to 2018, showed symptoms suggestive of CF during infancy, childhood, adolescence, or later. An interesting finding is that 38.8% of the FN patients manifested salt-loss syndrome (hypochloremic alkalosis) in the first year of life (associated or not with respiratory or nutritional/digestive symptoms). The median age at the diagnosis of Tuscan FN patients was 0.9 years. FN patients frequently have rare or unknown *CFTR* mutations compared with true-positive cases, and this confirms that a sweat test should be the primary test. Our results also show the importance of feedback of CF diagnoses in the CF screening centers. This study highlights the need for an improvement of CF NBS and the importance of maintaining vigilance toward clinical manifestations suggestive of CF. Having performed an efficient NBS test does not preclude a diagnosis of CF. A delay in diagnosis for FN patients can be shortened by a vigilant clinician.
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diagnostics-10-00446-t001_Table 1

###### 

Data from the 1992--2018 Cystic fibrosis newborn screening (CF NBS). Percentages as related to all cystic fibrosis (CF) cases of column are included in parentheses.

  ------------------------------------------------------------------------------------------------------------------------------------
                                              IRT1/IRT2 + LACT (1992--2010)   IRT1/IRT2 + LACT + IRT1/DNA (2011--2018)   Total
  ------------------------------------------- ------------------------------- ------------------------------------------ -------------
  Newborns screened for CF                    514,841                         231,845                                    746,686

  Newborns with negative screening            513,619                         231,227                                    744,846

  Non-CF newborns with negative screening\    513,603                         231,225                                    744,828
  (true negative)                                                                                                        

  CF newborns with negative screening\        16 (11.2%)                      2 (3.4%)                                   18 (8.9%)
  (false negative)                                                                                                       

  Number of sweat tests\                      1222                            618                                        1840
  (newborns with positive screening)                                                                                     

  CF newborns with positive screening\        112 (78.3%)                     50 (84.7%)                                 162 (80.2%)
  (true positive)                                                                                                        

  Non-CF newborns with positive screening\    1110                            568                                        1678
  (false positive)                                                                                                       

  CF newborns diagnosed with meconium ileus   15 (10.5%)                      7 (11.9%)                                  22 (10.9%)

  Sensitivity (%)                             87.50                           96.15                                      90.00

  Specificity (%)                             99.78                           99.75                                      99.77

  Positive predictive value (%)               9.16                            8.09                                       8.80

  Negative predictive value (%)               99.997                          99.999                                     99.997
  ------------------------------------------------------------------------------------------------------------------------------------

IRT: immunoreactive trypsin assay; LACT: meconium lactase dosage; DNA: *CFTR* panel analysis.

diagnostics-10-00446-t002_Table 2

###### 

Features of false-negative (FN) patients: genotype, symptoms, first immunoreactive trypsinogen dose (IRT1), age at diagnosis, pancreas status, and sweat test.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FN Patients   Year of Birth   IRT1 µg/L\   *CFTR* Mutation 1   *CFTR* Mutation 2   Symptoms and Signs Suggestive of CF               Age at Diagnosis   Pancreas Status   Sweat Test (Chloride mEq)
                                (Cutoff)                                                                                                                                    
  ------------- --------------- ------------ ------------------- ------------------- ------------------------------------------------- ------------------ ----------------- ---------------------------
  A             1993            \<55 (55)    G542X               D110H               asymptomatic\                                     22 years           PS                89-80
                                                                                     (family history)                                                                       

  B             1995            \<58 (58)    DF508               E831X               nasal polyposis                                   20 years           PS                104-96

  C             1996            \<58 (58)    DF508               unknown             respiratory                                       20 years           PS                58-42-72-83

  D             1997            \<60 (60)    G542X               unknown             respiratory +\                                    17 years           PS                62-67
                                                                                     nasal polyposis                                                                        

  E             1999            \<58 (58)    DF508               5T/12TG             respiratory                                       15 years           PS                78-100

  F             1999            \<58 (58)    DF508               unknown             failure to thrive + gastroenteric                 4 months           PD                110-115

  G             2001            39 (54)      DF508               G542X               nasal polyposis                                   5 years            PD                80-94

  H             2001            37 (54)      S737F               Del exon 22--24     salt-loss syndrome + respiratory                  1 year             PS                82-89

  I             2003            48 (54)      DF508               DF508               respiratory + failure to thrive + gastroenteric   4 months           PD                110-153

  L             2003            45 (54)      W1282X              DF311               salt-loss syndrome                                5 months           PS                60-63-85-93

  M             2005            47 (62)      DF311               Del exon 2          salt-loss syndrome + failure to thrive            4 months           PS                75-71

  N             2006            52 (57)      L206W               3659delC            salt-loss syndrome                                10 months          PS                90-65-156

  O             2006            41 (57)      L1065P              5T/13TG             respiratory                                       12 years           PS                52-61-40-69-101

  P             2008            31 (60)      S737F               S737F               salt-loss syndrome                                7 months           PS                45-46-93-64-98

  Q             2010            51 (63)      DF508               DF508               respiratory + failure to thrive + gastroenteric   4 months           PD                102-96

  R             2010            54 (63)      DF508               Delexon 22--24      respiratory + failure to thrive + gastroenteric   10 months          PD                125-125

  S             2015            15 (50)      E831X               G126D               salt-loss syndrome                                11 months          PS                67-74-70

  T             2016            27 (49)      N1303K              L997F               salt-loss syndrome + failure to thrive            11 months          PS                60-58-84-67
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PS: pancreas sufficiency; PD: pancreas deficiency.

diagnostics-10-00446-t003_Table 3

###### 

Frequencies of *CFTR* mutations in 360 cystic fibrosis *CFTR* alleles in Tuscany (324 *CFTR* alleles of true positive cases and 36 *CFTR* alleles of FNs).

  True-Positive Cases    False-Negative Cases                          
  ---------------------- ---------------------- ---------------------- ------
  DF508                  45.6                   DF508                  27.7
  G542X                  5.5                    G542X                  8.3
  L1065P                 3.7                    S737F                  8.3
  N1303K                 3.1                    Delexon 22--24         5.5
  E585X                  2.5                    L1065P                 2.7
  2789+5G-\>A            2.5                    W1282X                 2.7
  Delexon 22--24         2.2                    N1303K                 2.7
  R347P                  2.2                    Other rare mutations   33.3
  W1282X                 2.2                    Unknown                8.3
  T338I                  2.2                                           
  R553X                  1.8                                           
  S737F                  1.3                                           
  2183AA-\>G             1.3                                           
  Other rare mutations   22.8                                          
  Unknown                1.1                                           
